C25-140

Key Product Details

Product Description

C25-140 binds directly to TNF receptor-associated factor 6 (TRAF6) and inhibits its interaction with ubiquitin-conjugating enzyme Ubc13. C25-140 reduces TRAF6-Ubc13 activity and decreases NF-κB activation and inflammatory signaling in vitro. C25-140 exhibits selectivity for TRAF6 over other E3 ligases except cIAP1. In in vivo mouse models of autoimmune psoriasis and rheumatoid arthritis, the compound improves disease symptoms. The compound also suppresses the pro-inflammatory signaling activity of IL-17A and prevents its inhibitory effect on the anti-HBV action of IFN-α HepG2 cells.

Product Specifications for C25-140

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for C25-140

The following data is based on the product molecular weight 457.57.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.5 mM	4.37 mL	21.85 mL	43.71 mL
2.5 mM	0.87 mL	4.37 mL	8.74 mL
5 mM	0.44 mL	2.19 mL	4.37 mL
25 mM	0.09 mL	0.44 mL	0.87 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Zhang Interleukin-17A pretreatment attenuates the anti-hepatitis B virus efficacy of interferon-alpha by reducing activation of the interferon-stimulated gene factor 3 transcriptional complex in hepatitis B virus-expressing HepG2 cells. Virol.J. 2022 PMID: 35144643
• Brenke Targeting TRAF6 E3 ligase activity with a small-molecule inhibitor combats autoimmunity. J.Biol.Chem. 2018 PMID: 29950522

Product Documents for C25-140